Table 2 |
|||
|
Treatment-emergent adverse events through safety follow up (day 31): incidence ≥ 5% in any treatment group |
|||
|
Number (%) of patients |
|||
|
|
|||
|
Adverse event (AE) |
SC placebo + oral indomethacin (n = 77)1 |
SC rilonacept + oral indomethacin (n = 73)1 |
SC rilonacept + oral placebo (n = 75) |
|
|
|||
|
Any AE |
23 (29.9) |
34 (46.6) |
27 (36.0) |
|
Discontinuations due to AE |
2 (2.6) |
1 (1.4) |
1(1.3) |
|
Serious AE |
0 |
3 (4.1) |
0 |
|
Headache |
6 (7.8) |
4 (5.5) |
7 (9.3) |
|
Dizziness |
4 (5.2) |
3 (4.1) |
2 (2.7) |
|
|
|||
|
1Numbers differ from patient disposition since one patient was administered the wrong drug. |
|||
|
Terkeltaub et al. Arthritis Research & Therapy 2013 15:R25 doi:10.1186/ar4159 |
|||
